Brian T Bateman1, Uffe Heide-Jørgensen2, Kristjana Einarsdóttir3, Anders Engeland4, Kari Furu5, Mika Gissler6, Sonia Hernandez-Diaz7, Helle Kieler6, Anna-Maria Lahesmaa-Korpinen8, Helen Mogun9, Mette Nørgaard2, Johan Reutfors6, Randi Selmer5, Krista F Huybrechts1, Helga Zoega10. 1. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (B.T.B., K.F.H.). 2. Aarhus University Hospital, Aarhus, Denmark (U.H., M.N.). 3. University of Iceland, Reykjavik, Iceland (K.E.). 4. Norwegian Institute of Public Health, Oslo, and University of Bergen, Bergen, Norway (A.E.). 5. Norwegian Institute of Public Health, Oslo, Norway (K.F., R.S.). 6. University of Turku, Turku, Finland, and Karolinska Institutet, Stockholm, Sweden (M.G., H.K., J.R.). 7. Harvard T.H. Chan School of Public Health, Boston, Massachusetts (S.H.). 8. National Institute for Health and Welfare, Helsinki, Finland (A.L.). 9. Karolinska Institutet, Stockholm, Sweden; National Institute for Health and Welfare, Helsinki, Finland; Brigham and Women's Hospital, Boston, Massachusetts (H.M.). 10. University of Iceland, Reykjavik, Iceland, and University of New South Wales, Sydney, New South Wales, Australia (H.Z.).
Abstract
Background: β-Blockers are a class of antihypertensive medications that are commonly used in pregnancy. Objective: To estimate the risks for major congenital malformations associated with first-trimester exposure to β-blockers. Design: Cohort study. Setting: Health registries in the 5 Nordic countries and the U.S. Medicaid database. Patients: Pregnant women with a diagnosis of hypertension and their offspring. Measurements: First-trimester exposure to β-blockers was assessed. Outcomes were any major congenital malformation, cardiac malformations, cleft lip or palate, and central nervous system (CNS) malformations. Propensity score stratification was used to control for potential confounders. Results: Of 3577 women with hypertensive pregnancies in the Nordic cohort and 14 900 in the U.S. cohort, 682 (19.1%) and 1668 (11.2%), respectively, were exposed to β-blockers in the first trimester. The pooled adjusted relative risk (RR) and risk difference per 1000 persons exposed (RD1000) associated with β-blockers were 1.07 (95% CI, 0.89 to 1.30) and 3.0 (CI, -6.6 to 12.6), respectively, for any major malformation; 1.12 (CI, 0.83 to 1.51) and 2.1 (CI, -4.3 to 8.4) for any cardiac malformation; and 1.97 (CI, 0.74 to 5.25) and 1.0 (CI, -0.9 to 3.0) for cleft lip or palate. For CNS malformations, the adjusted RR was 1.37 (CI, 0.58 to 3.25) and the RD1000 was 1.0 (CI, -2.0 to 4.0) (based on U.S. cohort data only). Limitation: Analysis was restricted to live births, exposure was based on dispensed medication, and cleft lip or palate and CNS malformations had few outcomes. Conclusion: The results suggest that maternal use of β-blockers in the first trimester is not associated with a large increase in the risk for overall malformations or cardiac malformations, independent of measured confounders. Primary Funding Source: The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Söderström König Foundation.
Background: β-Blockers are a class of antihypertensive medications that are commonly used in pregnancy. Objective: To estimate the risks for major congenital malformations associated with first-trimester exposure to β-blockers. Design: Cohort study. Setting: Health registries in the 5 Nordic countries and the U.S. Medicaid database. Patients: Pregnant women with a diagnosis of hypertension and their offspring. Measurements: First-trimester exposure to β-blockers was assessed. Outcomes were any major congenital malformation, cardiac malformations, cleft lip or palate, and central nervous system (CNS) malformations. Propensity score stratification was used to control for potential confounders. Results: Of 3577 women with hypertensive pregnancies in the Nordic cohort and 14 900 in the U.S. cohort, 682 (19.1%) and 1668 (11.2%), respectively, were exposed to β-blockers in the first trimester. The pooled adjusted relative risk (RR) and risk difference per 1000 persons exposed (RD1000) associated with β-blockers were 1.07 (95% CI, 0.89 to 1.30) and 3.0 (CI, -6.6 to 12.6), respectively, for any major malformation; 1.12 (CI, 0.83 to 1.51) and 2.1 (CI, -4.3 to 8.4) for any cardiac malformation; and 1.97 (CI, 0.74 to 5.25) and 1.0 (CI, -0.9 to 3.0) for cleft lip or palate. For CNS malformations, the adjusted RR was 1.37 (CI, 0.58 to 3.25) and the RD1000 was 1.0 (CI, -2.0 to 4.0) (based on U.S. cohort data only). Limitation: Analysis was restricted to live births, exposure was based on dispensed medication, and cleft lip or palate and CNS malformations had few outcomes. Conclusion: The results suggest that maternal use of β-blockers in the first trimester is not associated with a large increase in the risk for overall malformations or cardiac malformations, independent of measured confounders. Primary Funding Source: The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Söderström König Foundation.
Authors: Brian T Bateman; Krista F Huybrechts; Michael A Fischer; Ellen W Seely; Jeffrey L Ecker; Anna S Oberg; Jessica M Franklin; Helen Mogun; Sonia Hernandez-Diaz Journal: Am J Obstet Gynecol Date: 2014-09-28 Impact factor: 8.661
Authors: Krista F Huybrechts; Gabriella Bröms; Lotte Brix Christensen; Kristjana Einarsdóttir; Anders Engeland; Kari Furu; Mika Gissler; Sonia Hernandez-Diaz; Pär Karlsson; Øystein Karlstad; Helle Kieler; Anna-Maria Lahesmaa-Korpinen; Helen Mogun; Mette Nørgaard; Johan Reutfors; Henrik Toft Sørensen; Helga Zoega; Brian T Bateman Journal: JAMA Psychiatry Date: 2018-02-01 Impact factor: 21.596
Authors: Sarah C Fisher; Alissa R Van Zutphen; Martha M Werler; Angela E Lin; Paul A Romitti; Charlotte M Druschel; Marilyn L Browne Journal: Hypertension Date: 2017-04-03 Impact factor: 10.190
Authors: Brian T Bateman; Pooja Bansil; Sonia Hernandez-Diaz; Jill M Mhyre; William M Callaghan; Elena V Kuklina Journal: Am J Obstet Gynecol Date: 2011-11-07 Impact factor: 8.661
Authors: Kristin Palmsten; Krista F Huybrechts; Mary K Kowal; Helen Mogun; Sonia Hernández-Díaz Journal: Pharmacoepidemiol Drug Saf Date: 2014-04-16 Impact factor: 2.890
Authors: Krista F Huybrechts; Kristin Palmsten; Jerry Avorn; Lee S Cohen; Lewis B Holmes; Jessica M Franklin; Helen Mogun; Raisa Levin; Mary Kowal; Soko Setoguchi; Sonia Hernández-Díaz Journal: N Engl J Med Date: 2014-06-19 Impact factor: 91.245
Authors: Yanmin Zhu; Brian T Bateman; Kathryn J Gray; Sonia Hernandez-Diaz; Helen Mogun; Loreen Straub; Krista F Huybrechts Journal: BMJ Date: 2020-05-20
Authors: Jeffrey N Bone; Akshdeep Sandhu; Edgardo D Abalos; Asma Khalil; Joel Singer; Sarina Prasad; Shazmeen Omar; Marianne Vidler; Peter von Dadelszen; Laura A Magee Journal: Hypertension Date: 2022-01-04 Impact factor: 9.897
Authors: Kristina Laugesen; Jonas F Ludvigsson; Morten Schmidt; Mika Gissler; Unnur Anna Valdimarsdottir; Astrid Lunde; Henrik Toft Sørensen Journal: Clin Epidemiol Date: 2021-07-19 Impact factor: 4.790